| 53.7 -0.65 (-1.2%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 66.64 | 1-year : | 75.33 |
| Resists | First : | 57.05 | Second : | 64.5 |
| Pivot price | 58.13 |
|||
| Supports | First : | 45 | Second : | 37.44 |
| MAs | MA(5) : | 56.16  |
MA(20) : | 56.76 |
| MA(100) : | 51.73 |
MA(250) : | 68.85 |
|
| MACD | MACD : | 1.6 |
Signal : | 2.4 |
| %K %D | K(14,3) : | 35.9 |
D(3) : | 46.3 |
| RSI | RSI(14): 48 |
|||
| 52-week | High : | 240 | Low : | 7.26 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SPRB ] has closed above bottom band by 16.7%. Bollinger Bands are 3.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 56.17 - 56.51 | 56.51 - 56.76 |
| Low: | 52.31 - 52.74 | 52.74 - 53.07 |
| Close: | 53.13 - 53.77 | 53.77 - 54.25 |
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
Tue, 08 Sep 2026
Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - Business Wire
Wed, 26 Aug 2026
Spruce Biosciences Announces Launch of MPS3BStudy.com - Investing News Network
Mon, 24 Aug 2026
Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026 - Business Wire
Fri, 14 Aug 2026
Spruce Biosciences (SPRB) sees AWM Investment disclose 5.1% equity stake - stocktitan.net
Wed, 29 Jul 2026
Spruce Biosciences, Inc. Revenue Breakdown – NASDAQ:SPRB - TradingView
Mon, 22 Jun 2026
Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs - Investing News Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 3.3 (%) |
| Held by Institutions | 76.8 (%) |
| Shares Short | 403 (K) |
| Shares Short P.Month | 416 (K) |
| EPS | -38.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 30.42 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40.1 % |
| Return on Equity (ttm) | -106 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -8 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -13.61 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -43 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -1.4 |
| PEG Ratio | 0 |
| Price to Book value | 1.76 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|